Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?Zacks Investment Research • 05/02/24
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingGlobeNewsWire • 04/12/24
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public OfferingGlobeNewsWire • 03/28/24
Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores BigInvestors Business Daily • 03/26/24
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated PatientsGlobeNewsWire • 03/26/24
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 03/08/24
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a BetZacks Investment Research • 03/06/24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 03/05/24
Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 03/01/24
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public OfferingGlobeNewsWire • 01/11/24
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/09/24
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 01/05/24
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to TradeZacks Investment Research • 11/30/23
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming MeetingsGlobeNewsWire • 11/28/23
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewsWire • 11/21/23
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesGlobeNewsWire • 11/16/23
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/14/23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23